<DOC>
	<DOCNO>NCT01944436</DOCNO>
	<brief_summary>Lewy body spectrum disorder common group neurodegenerative disease cause memory loss , behavioural motor disability impair quality life . Cognitive enhancer help people afflicted condition . However , people benefit treatment , others experience serious side effect . Side effect poor response lead hospitalization early institutionalization . Pharmacogenomics , study DNA variation influence drug effect , combine functional change brain imaging response cognitive enhancer patient Lewy body disease . The goal develop predictive test administer clinic aid physician ' choice initial medication . This reduce health care cost improve treatment Canadians suffer devastate disorder .</brief_summary>
	<brief_title>A Genetic Perfusion Study Response Cognitive Enhancers Lewy Body Disease</brief_title>
	<detailed_description />
	<mesh_term>Lewy Body Disease</mesh_term>
	<mesh_term>Galantamine</mesh_term>
	<mesh_term>Rivastigmine</mesh_term>
	<mesh_term>Donepezil</mesh_term>
	<mesh_term>Cholinesterase Inhibitors</mesh_term>
	<mesh_term>Nootropic Agents</mesh_term>
	<criteria>Inclusion criterion patient Lewy body spectrum disorder include : age &gt; 50 year ; mildmoderate dementia ( MiniMental State Exam [ MMSE ] &gt; 9 ) ; contact least four seven days/week responsible caregiver ; Hoehn &amp; Yahr stage â‰¤ 4. age &lt; 50 ; Severe dementia ( MMSE &lt; 9 ) ; contact &lt; 4 day week responsible caregiver ; Hoehn &amp; Yahr stage &gt; 4 .</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Pharmacogenomics</keyword>
	<keyword>Dementia Lewy body</keyword>
	<keyword>Adverse event</keyword>
	<keyword>Polymorphisms</keyword>
	<keyword>Acetylcholinesterase</keyword>
	<keyword>Parkinson 's Disease Dementia</keyword>
	<keyword>Cognitive enhancer</keyword>
	<keyword>Clinical efficacy</keyword>
	<keyword>Cytochrome P450</keyword>
	<keyword>Butyrylcholinesterase</keyword>
</DOC>